Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | IL6ST | P40189 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9758542 | 1.00 | NAAA (0.46) | NAAARAB9ANPC1LMNATP53 | |
| SCHEMBL30812536 | 1.00 | NAAA (0.46) | NAAARAB9ANPC1LMNATP53 | |
| SCHEMBL1915646 | 0.87 | NAAA (0.47) | NAAAHPGDIDH1PPARAFAAH | |
| SCHEMBL7346791 | 0.87 | NAAA (0.47) | NAAAHPGDIDH1PPARAFAAH | |
| SCHEMBL1915643 | 0.87 | NAAA (0.47) | NAAAHPGDIDH1PPARAFAAH | |
| SCHEMBL548889 | 0.87 | NAAA (0.50) | NAAAIDH1PPARAHDAC1FAAH | |
| SCHEMBL16063845 | 0.87 | NAAA (0.57) | NAAAIDH1PPARAHDAC1FAAH | |
| SCHEMBL31293011 | 0.87 | NAAA (0.57) | NAAAIDH1PPARAHDAC1FAAH | |
| SCHEMBL24049987 | 0.86 | NAAA (0.46) | NAAAIDH1PPARAHDAC1FAAH | |
| SCHEMBL20215398 | 0.86 | NAAA (0.46) | NAAAIDH1PPARAHDAC1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | EMORY UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | EMORY UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| WO-2017075590-A2 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | COCRYSTAL PHARMA, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075590-A2 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | COCRYSTAL PHARMA, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-7414156-B2 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | WARNER LAMBERT CO. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20050124830-A1 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | HOGE GARRETT S II (US) | 2005-06-09 | — | — | US | disclosed |
| US-6855849-B2 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | WARNER-LAMBERT COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040138487-A1 | Bisphospholane ligands with metals for hydrogenation catalysts for enantiomorphs | HOGE GARRETT STEWART | 2004-07-15 | — | — | US | disclosed |
| EP-1171416-B1 | 3-BICYCLOARYL-2-AMINOMETHYL BICYCLOALKANES AS SEROTONINE REUPTAKE INHIBITORS | LILLY CO ELI (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-6689915-B2 | AS CATALYSTS FOR USE IN ASYMMETRIC TRANSFORMATION REACTIONS TO PROVIDE HIGH ENANTIOMERIC EXCESSES OF FORMED COMPOUNDS | WARNER-LAMBERT COMPANY LLC | 2004-02-10 | — | — | US | disclosed |
| US-20030073868-A1 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | WARNER-LAMBERT COMPANY | 2003-04-17 | — | — | US | disclosed |
| US-20020143214-A1 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | HOGE GARRETT STEWART (US) | 2002-10-03 | — | — | US | disclosed |
| EP-1243591-A2 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | WARNER-LAMBERT COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1171416-A1 | 3-BICYCLOARYL-2-AMINOMETHYL BICYCLOALKANES AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY LIMITED (GB) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061539-A1 | 3-BICYCLOARYL-2-AMINOMETHYL BICYCLOALKANES AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
| US-5068345-A | Oxazolidinone aldol adduct | EASTMAN KODAK COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| US-5012000-A | Total synthesis of chiral 2-amino-1,3-diols | EASTMAN KODAK COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124830-A1 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | PHOSPHO1, PPIP5K2, BPGM | NAAA 240/4885RAB9A 433/4885NPC1 3069/4885 |
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | DERA, DPYD, DUS2 | NAAA 3397/4885RAB9A 2174/4885NPC1 4526/4885 |
| US-20020143214-A1 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | PHOSPHO1, PPIP5K2, PFKFB2 | NAAA 316/4885RAB9A 876/4885NPC1 3220/4885 |
| US-20030073868-A1 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | PHOSPHO1, PPIP5K2, DNM2 | NAAA 320/4885RAB9A 549/4885NPC1 3017/4885 |
| US-20040138487-A1 | Bisphospholane ligands with metals for hydrogenation catalysts for enantiomorphs | BPGM, PHOSPHO1, PPIP5K2 | NAAA 359/4885RAB9A 859/4885NPC1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.